HLA-C and neoplasm: Several factors contribute to this variability, including inappropriate adjuvants [3, 4], tumor cell heterogeneity [5, 6], antigen loss within tumors [7], diminished MHC expression [8], inadequate T cell infiltration in tumor tissues [9], and immune suppression via dysfunctional T cells [10].